Celgene Corporation

Celgene — Proxy Contest (May 2018)

28 slides from Celgene's proxy contest presentation, May 18, 2018

  1. Slide 1: Business Update and Overview of Independent Board Leadership

    Business Update and Overview of Independent Board Leadership May 2018 C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  2. Slide 2: Forward Looking Statements and Adjusted Financial Information

    Forward Looking Statements and Adjusted Financial Information 2 This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estima

  3. Slide 3: Executive Summary

    Executive Summary 3 • We are accelerating diversification by advancing medicines to transform the treatment of diseases, within hematology, oncology, inflammation and immunology • We have a robust R&D engine delivering first - and best - in - class programs through our centers of excellence and part

  4. Slide 4: Our Mission and Vision

    Our Mission and Vision 4 Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with cancer, immune - inflammatory, and other unmet medical needs

  5. Slide 5: Deploying a Strategy to Grow Through 2020 and Beyond

    Deploying a Strategy to Grow Through 2020 and Beyond Execute Delivering on 2020 Accelerate Positioning to Grow Beyond 2020 Expand Creating Sustainable Growth 5

  6. Slide 6: 2017 Performance Highlights

    2017 Performance Highlights 6 Financial Highlights • Net product sales: $12,973 million, an increase of 16% • Total revenue: $13,003 million, an increase of 16% • GAAP Net income: $2,940 million, an increase of 47% • Diluted GAAP EPS: $3.64, an increase of 46% • Adjusted net income*: $6,016 million,

  7. Slide 7: Long-Term Value Creation for Shareholders

    Long - Term Value Creation for Shareholders 7 Five - Year Cumulative Total Shareholder Return Assessing five - year cumulative total shareholder return, a $ 100 investment in the Company’s Common Stock on December 31 , 2012 would have grown 166 % to approximately $ 266 on December 31 , 2017 , as dep

  8. Slide 8: Strong Volume-Driven Growth Expected in 2018

    Strong Volume - Driven Growth Expected in 2018 8 % 18 EPS Y/Y growth* ~$9.5B Diluted EPS* ~$1.9B + ~$1.0B *Adjusted financial measure which includes the impact of our acquisition of Juno Therapeutics Inc., which is expected to be d ilu tive to adjusted EPS in 2018 by approximately $0.50. EPS Y/Y gro

  9. Slide 9: Accelerating Diversification by Advancing Medicines to Transform Treatment of Diseases

    Multiple Myeloma Accelerating Diversification by Advancing Medicines to Transform the Treatment of Diseases 9 Market Opportunity $27B Incidence 60K HEMATOLOGY & ONCOLOGY Non - Hodgkin Lymphoma Market Opportunity $17B Incidence 90K Myeloid Diseases Market Opportunity $5B Incidence 65K Psoriasis / Pso

  10. Slide 10: R&D Engine: Building a Pipeline of Next-Generation Growth Drivers

    R&D Engine Building a Pipeline of Next - Generation Growth Drivers 10 Centers of Excellence Partner Network Epigenetics Immuno - Oncology Inflammation & Immunology Protein Homeostasis Neuroscience & Imaging Innovation Engine Advancing 8 New Programs into the Clinic ▪ Next - Gen CELMoD ® ▪ Ph I for M

  11. Slide 11: Delivering Industry-Leading Growth Through 2020

    Delivering Industry - Leading Growth Through 2020… Late - stage Pipeline with Potential to Add Over $16B in Incremental Peak Revenue Through 2030 11 …And Positioned to Grow Beyond 2020 Expect to Launch Ten Potential Blockbusters Adj. Diluted EPS Total Revenue ~19% CAGR 14.5% CAGR Note: CAGR calculat

  12. Slide 12: Enhancing Our Board and Management Team

    Enhancing Our Board and Management Team to Fully Capitalize on the Next Innovation Cycle 12 • Following the appointment of two new independent directors in 2018, and four since 2015, we continue to evaluate opportunities to enhance our Board’s diversity and independence as part of ongoing efforts to

  13. Slide 13: Board Structured to Provide Independent Oversight and Diversity

    Board Structured to Provide Independent Oversight and Diversity 13 Active Independent Oversight Practices 1 Source : Spencer Stuart Board Index 2016 . x Independent Lead Director role with responsibilities in line with industry norms x Regular Board assessment of optimal leadership structure x Indep

  14. Slide 14: Board Composition Provides Diversity and Balance of Skill Sets

    Board Composition Provides Diversity, Balance of Skill Sets, and Other Experience Relevant to Our Business 14 Celgene’s Board has implemented practices that enhance independent oversight of management The Nominating Committee assesses the needs of the Board and the Company to recruit directors who h

  15. Slide 15: Independent Lead Director Provides Active Oversight

    Independent Lead Director Provides Active Oversight 15 Michael D. Casey, Independent Lead Director • Mr . Casey’s breadth of experience in management, operations, and corporate governance led independent directors to appoint him to this Board leadership role • Mr . Casey has held several prominent r

  16. Slide 16: Responsive to Shareholder Feedback

    Responsive to Shareholder Feedback 16 We maintain a robust investor outreach program that provides ongoing feedback concerning our compensation programs and other governance matters Key Highlights and Actions Taken • We proactively reach out to shareholders representing more than 50 % of the outstan

  17. Slide 17: Effective Board Leadership Structure Best Serves Shareholder Interests

    Effective Board Leadership Structure Best Serves Shareholder Interests 17 The Board recommends that shareholders vote against the proposal to require an independent Board Chairman, as it will impede the Board’s flexibility in determining the Company’s leadership structure that best serves the Compan

  18. Slide 18: Executive Compensation Aligns Pay and Performance

    Executive Compensation Aligns Pay and Performance 18 Celgene’s Board has implemented practices that enhance independent oversight of management As supported by 95% Say on Pay vote for our 2017 executive compensation for NEOs A significant percentage of compensation awards to Celgene’s NEOs is variab

  19. Slide 19: Recognized for Commitment to Our Patients and the Broader Community

    Recognized for Commitment to Our Patients and the Broader Community 19 Underlying our Company’s culture is a strong belief in corporate responsibility that is predicated on our purpose, values, an d behaviors, which are the foundation of our approach to ethical and responsible business activities 1

  20. Slide 20: Use of Non-GAAP Financial Measures and Reconciliation Tables

    Use of Non - GAAP Financial Measures and Reconciliation Tables C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  21. Slide 21: Use of Non-GAAP Financial Measures

    Use of Non - GAAP Financial Measures 21 Use of Non - GAAP Financial Measures In addition to financial information prepared in accordance with U . S . GAAP, this document also contains certain non - GAAP financial measures based on management’s view of performance including : Adjusted research and de

  22. Slide 22: Use of Non-GAAP Financial Measures

    Use of Non - GAAP Financial Measures 22 Share - based Compensation Expense : We exclude share - based compensation from our adjusted financial results because share - based compensation expense, which is non - cash, fluctuates from period to period based on factors that are not within our control, s

  23. Slide 23: Use of Non-GAAP Financial Measures

    Use of Non - GAAP Financial Measures 23 Certain Other Items : We exclude certain other significant items that may occur occasionally and are not normal, recurring, cash operating expenses from our adjusted financial results . Such items are evaluated on an individual basis based on both the quantita

  24. Slide 24: Use of Non-GAAP Financial Measures: Long-Term Targets

    Use of Non - GAAP Financial Measures 24 Long - Term Targets A reconciliation of long - term adjusted financial targets to the most comparable GAAP measures cannot be provided because we are unable to forecast with reasonable certainty many of the items necessary to calculate such comparable GAAP mea

  25. Slide 25: Reconciliation Tables

    Reconciliation Tables Dy & ws or spor ad sot $ ets ba sy oneal ano (cs ee Femipy- aes [ay 8 ome sean face, oe) 3) ow sana gg inda pa ‘mor me a 2 8 eam te pa "a aa) 90 > rE o aan Cnn og rug Rip qe ys SoD ie Yan sae an pan cs so 6 sr apo poe pep ° aden indameomapawemee sods eure po Hes “conser pened B

  26. Slide 26: Reconciliation Tables

    Reconciliation Tables 26 Explanation of adjustments: (1) Exclude share - based compensation expense totaling $162 for the three - month period ended December 31, 2017 and $155 for the three - month period ended December 31, 2016. Exclude share - based compensation expense totaling $644 for the twelv

  27. Slide 27: ‘rpite fuao nop ete ate ies ssa ues apna tes oD

    ar ‘rpite fuao nop ete ate ies ssa ues apna tes oD TH aT sospogy st phan os srs poy -wrtsanos page it nse pi ie eos avv0- wroozuos pares se sana ne i 2 pany esa: pnbie Dv wo exumuipran awadvong uo © ‘espe qr a me pS ‘somo oo ow wo series ete quay 3 ar » be pane ty o cy semadsnssrporsgupeoominnns peg

  28. Slide 28: Business Update and Overview of Independent Board Leadership

    May 2018 C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE Business Update and Overview of Independent Board Leadership

Celgene — Proxy Contest (May 2018) on 6ix